TORRANCE, CA, UNITED STATES
Arrivals (12 mo)
0
0 active ports
Active Ports
0
Distinct US ports with vessel activity
Compliance
Clear
6 lists screened
Data compiled from FMC Licensed Carriers & OTIs, OpenSanctions, OFAC SDN, BIS Consolidated Screening List · As of 2026-04-26 · Updates monthly
Search of the OFAC SDN list for “MSD LINE, INC.” returned no matches.
Search of the BIS CSL for “MSD LINE, INC.” returned no matches. This covers the BIS Entity List, Denied Persons List, OFAC SDN, ITAR Debarred, and 10 other U.S. export control lists.
LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS IN THE BROAD POPULATION AND TO 37 MONTHS IN HRD-POSITIVE PATIENTS AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER
View on SEC.gov →LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC CANCER
View on SEC.gov →LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM GERMLINE BRCA-MUTATED METASTATIC PANCREATIC CANCER
View on SEC.gov →LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANCREATIC CANCER
View on SEC.gov →FORM 11-K: MSD PUERTO RICO SAVINGS & SECURITY PLAN (MRK 12.31.19)
View on SEC.gov →LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER
View on SEC.gov →LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER
View on SEC.gov →FORM 11-K: MSD PUERTO RICO SAVINGS & SECURITY PLAN (MRK 12.31.18)
View on SEC.gov →LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR BRCA1/2 OR ATM-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
View on SEC.gov →Source: SEC EDGAR Full-Text Search
Data Sources
No sanctions match
No exact name match found in OpenSanctions global database. This is not a guarantee of compliance — always verify through official channels.
Source: OpenSanctions (OFAC SDN, EU, UN, and 40+ additional lists)
Search the Consolidated Screening List (BIS, OFAC, DDTC) and global sanctions lists.
Search Screening List